Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of sitagliptin + metformin tablets vs Janumet in healthy Thai volunteers under fed conditions
TCTR20220505003Phase 1Not yet recruiting
- Sponsor
- Bio-innova
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sitagliptin + metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Bio-innova. Primary endpoint: Bioequivalence based on pharmacokinetic parameters of sitagliptin and metformin. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
sitagliptin + metformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on TCTR20220505003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20220505003.